The content on this site is intended for healthcare professionals only
In a press conference at SABCS 2014, Prof Rakovitch discusses the use of a multigene test called Oncotype DX DCIS Score (DCIS Score) as a predictor of risk of disease recurrence for patients with ductal carcinoma in situ (DCIS).
DCIS Score may be a good predictor of whether a patient with DCIS who was treated with breast-conserving surgery alone would experience recurrence of DCIS or invasive breast cancer in the same breast.
Read the news story here or watch the interview here.
BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer
SABCS 2025: Latest developments in multigene testing in early breast cancer
AI-Based sTIL analysis expands identification of HER2+ BC patients benefiting from pertuzumab
Insights into germline genetic screening of breast cancer patients
New classification for identifying HR myeloma based on cytogenetic abnormalities
Cancer mutation prediction using artificial intelligence
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Best practice in HRRm testing in patients with metastatic prostate cancer
Looking at real world evidence on PSA testing in prostate cancer
